The main purpose of the trial is to advance our knowledge on the possible mechanism underlying the catabolic effects of long-term treatment with glucocorticoid.

Long-term treatment with glucocorticoid induces a general state of catabolism and increases insulin resistance. The underlying mechanisms are insufficiently characterized, however glucocorticoid induced changes of Growth Hormone (GH) and the Insulin-like growth factor I (IGF-I) appear to be of outmost importance.

We wish to investigate the mechanism behind glucocorticoid induced catabolism and insulin resistance.

More specific we wish to investigate:

• Whether glucocorticoid induces IGF-I inhibiting substances in serum or interstitial fluid that block the ability of IGF-I to phosphorylate its receptor in vitro
• Whether glucocorticoid inhibits intracellular IGF-I and insulin signaling in vitro and in vivo
• The mechanisms by which growth hormone counteracts the CG-mediated inhibition of IGF-I action

Inclusion Criteria:

• signed and dated informed consent
• healthy subjects
• sex: male
• age 20-30 years
• BMI 19-26 kg/m2
• normal HbA1c

Exclusion Criteria:

• suspected og known allergy to the trial drug or similar medications.
• known current illness including diabetes mellitus, ischemic heart disease or cardiac arrhythmia.
• Daily drug intake (excluding Over-the-Counter medicines).
• Known or previous mental illness
• Current participation or previous participation in experiments using ionizing radiation for a year prior to inclusion in this study.
• Participation in a larger X-ray examinations in trial period.